Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based...

Area of Science:

• Immunology and Genetics
• CRISPR/Cas9 Gene Editing Applications

Background:

• Immune system disorders can cause autoimmunity, inflammation, and cancer.
• Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are chronic relapsing intestinal inflammatory conditions.
• Hundreds of genes are linked to IBD, but identifying therapeutic targets is challenging due to complex pathology and limitations in functional characterization tools.

Purpose of the Study:

• To develop and validate a novel model system for investigating therapeutic targets in immune-related diseases.
• To assess the feasibility of using CRISPR/Cas9 gene editing for in vivo functional genomics in the immune system.
• To demonstrate the utility of this approach for evaluating potential drug targets, exemplified by CD40.

Main Methods:

• Utilized clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated endonuclease (Cas9)-based technologies for gene editing in mice.
• Focused gene editing within the hematopoietic compartment to reconstitute the immune system.
• Employed a cluster of differentiation 40 (CD40) agonistic antibody to induce a colitis model for target validation.

Main Results:

• CRISPR/Cas9-mediated editing successfully modified genes within the immune system in vivo.
• CRISPR/Cas9-edited mice were generated more rapidly and cost-effectively compared to traditional genetically modified mice.
• The model system demonstrated significant advantages, including the ability to study embryonic lethal targets.

Conclusions:

• CRISPR/Cas9 gene editing provides an efficient and versatile platform for in vivo immune system research.
• This method accelerates the identification and functional characterization of therapeutic targets for complex immune-mediated diseases like IBD.
• The study validates the use of CRISPR/Cas9 in conjunction with disease models (e.g., CD40-induced colitis) for preclinical target assessment.